INTRODUCTION
============

Presently Alzheimer's disease (AD) therapies are limited by the availability of just two groups of drugs with one group consisting of just one drug. Acetylcholine esterase inhibitors increase the neuronal acetylcholine amounts, whereas memantine, an antagonist at the neuronal *N*-methyl [D]{.smallcaps}-aspartate (NMDA) receptor, reduces a neuronal overstimulation caused by the neurotransmitter glutaminic acid ([@B6]; [@B31]). Both the loss of acetylcholine and the neuronal overstimulation contribute to the decay of neurons and thus the AD progression. However, the patient benefit of the present drugs is poor and limited to the early stage of the disease ([@B59]; [@B48]). Memory, cognition, and daily behavior for life managing is hardly improved by the drugs in later stages of a severe AD ([@B59]; [@B48]). It is known that AD is a multifactorial disease which means that different pathophysiological factors all contribute to the AD progression ([@B14]). Most important hallmarks are the protein deposites which are found inside and outside the neuronal cells, namely the extracellular Aβ plaques and the intracellular neurofibrillary tangles (NFTs; [@B33]; [@B46]).

However, both proteins and their precursors are known to play a central role in the neuronal decay and disease progression. While a toxicity of the Aβ plaques is still under debate, their soluble precursors of non-aggregated Aβ proteins are toxic in various ways also by the formation of NFTs as a result of aggregation of a hyperphosporylated and misfolded tau protein as will be discussed later ([@B30]; [@B38]; [@B33]; [@B46]). Such tau protein can no longer support the intracellular transport mediated by the microtubules and with the loss of neuronal function the cell is dedicated to undergo apoptosis ([@B15]; [@B26]). Protein kinases are known to mainly contribute to these toxic events as they play a central role in the cellular pathways of regulated cell function and division.

With the understanding of various protein kinase functions the question of developing inhibitors as potential AD therapeutics has arisen. Protein kinase inhibitors are long established in cancer therapies where they regulate the overactivity of protein kinases which lead to uncontrolled cell divisions, cell migration, and cellular invasion ([@B19]; [@B69]). The toxicity of such anticancer protein kinase inhibitors has always been a critical question of causing toxic or undesired side-effects ([@B23]). Viewing the years of research in this field multitargeting protein kinase inhibitors established and are well tolerated by patients with only limited side-effects ([@B19]). So there are certain perspectives that protein kinase inhibitors for AD therapy may show promising effects in the pathophysiological AD process on one hand and for a more effective therapy on the other hand with respect to the knowledge that present drugs are no real perspective drugs to effectively influence the disease progression. The review will give a short summary of the early protein kinase inhibitors which target early known single target structures. Such early protein kinase inhibitors have been developed to reduce the activity of tau protein hyperphosphorylating kinases which have been found partly overactive or overexpressed in respective neuronal cells in AD brains and thus mainly contribute to the aggregation and loss of function of the hyperphosphorylated tau. Then novel inhibitors will be viewed which address novel targets with evidence for the AD progression and those which are dedicated to a multitargeting of more than one target structure.

EARLY PROTEIN KINASE INHIBITORS
===============================

Tau protein has been the main target structure for protein kinase inhibitors since tau protein was found hyperphosphorylated in AD brains. The tau protein hyperphosphorylation results in dissociation from the microtubules the function of which is supported by tau protein ([@B28]). Moreover, the hyperphosphorylation causes a loss of solubility and leads to the formation of paired helical filaments (PHFs) which further aggregate to NFTs ([@B2]; [@B27], [@B28]). The reason for the tau protein hyperphosphorylation is an imbalance of phosphorylation and dephosphorylation of tau. This imbalance is partly driven by a reduced tau protein dephosphorylation or by an overactivity of the phosphorylating protein kinases ([@B14]; [@B60]; [@B42]; [@B28]). Glycogen synthase kinase (GSK) 3β plays a central role in the tau phosphorylation process. It has been reported that 31% of the pathological phosphorylation sites of tau protein are phosphorylated by GSK3β ([@B28]). GSK3β has been found co-localized with NFTs and is found overexpressed in AD brains with increased activity ([@B43]; [@B22]). Toxic Aβ is known to increase the activity of GSK3β which contributes to an increased Aβ production via the tau phosphorylation ([@B13]; [@B55]). Therefore GSK3β forms a link of Aβ toxicity and tau pathology ([@B28]). Lithium as an early GSK3β inhibitor reduced tau phosphorylation and prevented reversed aspects of tau pathology in animal models ([@B56]). However, treatment of AD patients with mild AD in the early disease states showed no improvement in cognition ([@B11]). The result correlated with unchanged AD biomarkers in the cerebrospinal fluid (CSF) of the patients, namely phosphorylated tau, total tau, and toxic Aβ ([@B11]). Several GSK3β inhibitors are under development belonging to the paullone, indirubin, and the maleimide families. However, no representative of these inhibitor groups reached clinical trials so far. Reasons for their failure have been proven cytotoxic effects.

The other important tau protein kinase which is involved in pathophysiological tau protein phosphorylation is the cyclin dependent kinase 5 (cdk5). The normally cdk5 regulating protein p35 is found truncated in AD brains to 25 amino acids. This protein p25 leads to a constitutive activation of cdk5 and thus causes the pathophysiological tau phosphorylation ([@B40]). The hyperphosphorylated tau protein dissociates from the microtubules and forms NFTs on cdk5 induction by p25 ([@B7]; [@B35]). Also NFTs are phosphorylated by cdk5 action ([@B3]; [@B12]). Cdk5 phosphorylated tau becomes a better substrate for GSK3β so that excessive tau phosphorylation proceeds ([@B52]). Moreover, cdk5 promotes apoptosis in AD brains which may follow Aβ toxicity influenced by the hyperphosphorylated tau or by remaining p35 protein ([@B10]; [@B63]).

From the number of cdk inhibitors which were all non-selective like flavoperidol a pan-cdk inhibitor investigated for cancer therapy, cdk5-selective so-called CP-inhibitors were reported with nanomolar affinities and the ability to cross the blood brain barrier ([@B66]). They were described to reduce increased Aβ levels on p25 overexpression. However, as far as known these inhibitors remained in preclinical states.

NOVEL INHIBITORS
================

SINGLE PROTEIN KINASE TARGETING OF CDK5, P38, JNK, Erk, CK, and DYRK1A
----------------------------------------------------------------------

Due to the significant role of cdk5 in tau phosphorylation there have been ongoing efforts to develop novel inhibitors of the kinase which have been structurally based on the cdk inhibitor roscovitine (seliciclib) as a trisubstituted purine compound (**Figure [1](#F1){ref-type="fig"}**).
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Beside cdk5 roscovitine inhibits several cdks like cdk1, cdk2, or cdk9 in micromolar concentrations ([@B5]). It presently undergoes clinical trials of various types of cancer ([@B62]). However, roscovitine crosses the blood brain barrier and this advantage might have driven further studies because only about 2% of small molecule inhibitors are able to penetrate into the CNS ([@B32]; [@B39]). One structurally varied compound has been DRF 53 with a 2-pyridyl residue attached to the 4-position of the benzylamine substituent. With a similar cdk inhibition profile the toxic properties increased compared to roscovitine so that it is suggested to be used as anticancer agent like roscovitine ([@B5]). In a recent paper the 2-pyridyl residue has been changed by both a 3- and a 4-pyridyl residue ([@B8]). More favourable cdk5 inhibition data resulted in nanomolar ranges. Docking studies in the ATP binding pocket demonstrated a hydrogen bonding of the 4-pyridyl nitrogen to the Nε of Lys89 of the protein backbone to explain the increased activity. However, beside cdk5 also cdk2 was inhibited and all derivatives were toxic ([@B8]).

P38 protein kinase belonging to the mitogen activated protein kinases (MAPKs) is a tau protein phosphorylating kinase which contributes to tau protein dissociation from the microtubules and facilitates a further tau aggregation ([@B28]). In AD brains Aβ activates p38 isoforms p38α und p38β via activated glia ([@B49]). In the following proinflammatory cytokines are produced like interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα) ([@B53]). So nanomolar active p38 inhibitor SB-239063 is able to reduce the inflammatory cytokine production ([@B61]).

Erk isoforms 1 and 2 contribute to abnormal tau protein phosphorylation including the formation of pathological tau conformations ([@B41]; [@B28]). So the inhibition of Erk promises a reduced tau pathology. FR-180204 is the sole selective Erk inhibitor described so far ([@B36]).

Finally, JNKs of the MAPK family have been interesting target structures because they also contribute to tau phosphorylation. JNK activation is mediated by toxic Aβ fragments ([@B45]). However, activated JNKs also increase the γ-secretase activity and thus contribute to increased toxic Aβ levels resulting from the amyloid precursor protein (APP) by γ-secretase cleavage ([@B54]). Both MAPKs p38 and JNK have been co-purified with NFTs in AD brains ([@B70]). So JNKs are potential AD-therapeutic target structures. SP-600125 is a potent JNK isoform inhibitor ([@B4]). However, JNK3 is the known isoform which mediates the toxic response to Aβ with a greater role in the regulation of toxicity in brain than the other isoforms JNK1/2 ([@B45]). So it would be of benefit to develop a more exclusive JNK3 inhibitor.

Casein kinase isoforms CK1δ and CK1ε are expressed in brain and are mainly involved in the pathophysiological tau phosphorylation with 26% of those tau amino acids being phophorylatated by CK1 ([@B18]; [@B28]). CK1δ mRNA levels as well as the kinase itself are found mainly increased in AD brains up to 30-fold ([@B68]). CK1 has been found co-localized with NFTs like GSK3β being active in the tau phosphorylation of NFTs ([@B21]; [@B50]). Moreover, CK phosphorylation of tau sites facilitates the dissociation from the microtubules ([@B28]). Similar to GSK3β Aβ peptides activate CK thus triggering the tau pathology which on the other hand increases Aβ ([@B55]; [@B9]). Furthermore, CK1ε is known to play a role in the APP processing, likely by regulating the activity of γ-secretase which contributes to the formation of the toxic Aβ peptides. CK is additionally a priming kinase for GSK3β and has a regulatory role in cdk5 function ([@B18]).

Thus, CK is an interesting target structure for AD relevant protein kinase inhibitors, because the AD overactivity of the kinase may be regulated by an inhibitor without effecting the basic activity in cells. The presently known CK inhibitors IC-261 and tetrabromocinnamic acid (TBCA) are poor inhibitors with activities in partly higher micromolar ranges ([@B29]; [@B37]).

Dual-specificity tyrosine phosphorylation-regulating kinase 1A (DYRK1A) phosphorylates tau and transcription factor cAMP Response Element Binding (CREB) which is involved in learning and memory ([@B67]). Aβ peptides increase DYRK1A mRNA levels in AD brains ([@B17]). However, tau phosphorylation of DYRK1A is reported to be triggered by GSK3β ([@B17]). Interestingly, DYRK1A phosphorylates serine 202 of tau protein and this phosphorylation induces a conformational change of tau which is pathological ([@B28]). Thus, DYRK1A emerged to an interesting protein kinase for a tau-directed therapy. Harmine is an early DYRK1A inhibitor which inhibits not only the enzyme itself but also its tyrosine autophosphorylation ([@B51]). While harmine is a promising inhibitor with activities in nanomolar ranges, recent structural changes in the molecular skeleton by replacing the indole nitrogen by an oxygen or a sulfur atom and by replacing the annelated pyridine in the β-carboline scaffold by a pyrimidine led to decreases in activity ([@B24]). Moreover, it remains of doubt whether DYRK1A is a favourable target kinase because an inhibition would have negative consequences for the CREB phosphorylation. This phosphorylation is necessary for learning and memory processes which are both impaired in AD patients.

MULTITARGETING
--------------

One GSK3β inhibitor named tideglusib (NP-12) with a thiadiazolidinone scaffold presently undergoes phase 2 of clinical trials (**Figure [2](#F2){ref-type="fig"}**).
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In contrast to the other GSK3β inhibitors which are competitive inhibitors of ATP in the ATP-binding pocket NP-12 is a non-competitive inhibitor which was reported to reduce tau phosphorylation and amyloid depositions in brain and prevent neuronal death and cognitive deficits in animal models (http://clinicaltrials.gov/ct2/results?/term = Noscira, 2010). Moreover, NP-12 was identified as nuclear receptor PPARγ agonist which mediated effective anti-inflammatory and neuroprotective properties ([@B25]).

In recent studies two inhibitors of the MAPK family have been investigated in their effects in Aβ-injected rats ([@B1]). U0126 is an inhibitor of MEK1 and 2 which regulates the activity of Erk1 and 2, while PD169316 is a p38 inhibitor. Aβ activates MAPKs p38, Erk, and JNK. This activation causes a mitochondrial dysfunction by disturbance of the mitochondrial biogenesis. In early states of AD this mitochondrial abnormality is responsible for brain energy depletions. Aβ causes deficits in learning, memory and cognition as demonstrated by the behavioral changes of the rats after Aβ-treatment. The inhibitor applications led to increased levels of c-fos as activated gene which contributes to long-term memory processes. Moreover, the levels of CREB increased. The transcription factor is not only involved in early processes of long-term memory as discussed but also regulates the expression of factors PGC-1α and of NRF-1 ([@B20]; [@B64]). Both factors play a role in the biogenesis of mitochondria which are dysregulated in pathological settings like AD ([@B64]). So beside the role of MAPK inhibitors in a potential tau phosphorylation and tau pathology as discussed both inhibitors may show benefit for an improvement of memory and mitochondrial impairment and thus play a neuroprotective role against Aβ-mediated deficits.

Another MAPK family inhibitor MW01-2-069A of the protein kinase p38α further profiled in Aβ-related studies and by molecular properties ([@B34]). The selectivity in binding to the p38 isoform α could be reasoned with the favourable binding of the 4-pyridyl-residue in the ATP binding pocket which allows hydrogen bonding to the amide function of Gly110 of the protein backbone. Furthermore, the phenyl residue finds an optimized location in the neighbored hydrophobic binding pocket. P38α inhibitors have been discussed above to reduce the production of proinflammatory cytokines ([@B16]). MW01-2-069A was demonstrated to attenuate Aβ-mediated decreases of synaptophysin as a presynaptic protein. The downregulation of synaptophysin causes synaptic dysfunctions in the hippocampus and following hippocampal behavioral deficits. Favorably, the compound passes the blood brain barrier and proved to be metabolically stable to an extent of 70% ([@B34]). However, the inhibitory activity in submicromolar ranges has to be considered critically with respect to later clinical studies.

The protein kinase Rock has been demonstrated to be activated in neurites surrounded by amyloid deposites ([@B44]). The following outgrowth of the neurites could be protected by Rock inhibitor Y-27632. Moreover, an amyloid-induced loss of synapses could be retracted, so that novel synapse formation were observed. Furthermore the Rock inhibitor interfered with the APP processing by an increase of the α-secretase activity leading to less toxic Aβ ([@B47]).

1-Aza-9-oxafluorenes discovered as moderate cdk1 inhibitors first have been further developed as selective GSK3β inhibitors with a 3-carbonyl amide function at the 3-position of the molecular skeleton ([@B65]) and a loss of the cdk1 inhibition. While the pyridine nitrogen atom of the 3-carbonyl derivatives showed optimized hydrogen bonding to the NH function of amino acid Val135 of the protein backbone, the NH amide function bound to carbonyl amide function of Thr138 via a water molecule. Further variations at the molecular scaffold led to the benzo-annelated lead compounds which further profiled as cdk1, gsk3β and cdk5 inhibitors ([@B57]). The binding mode of those benzo-annelated naphtho compounds to the protein kinase backbone was demonstrated to be inverse compared to the early 1-aza-9-oxafluorenes with an orientation of the 3-substituent within the hydrophobic binding pocket nearby the gatekeeper amino acids ([@B65]; [@B57]). One nanomolar active 3-hydroxy compound showed exclusive cdk1, gsk3β and cdk5 inhibition properties and proved to be non-toxic in various cellular assays ([@B58]). It effectively inhibited tau phosphorylation of various tau amino acids and has been suggested for further tau pathology studies in tau mice models.

CHALLENGES
==========

During the last decades of AD research it has become more obvious that AD is not only a multifactorial disease with various pathological events which contribute to the diseases progression but also a cross-linked disease. Aβ toxicity has been demonstrated to increase tau pathology. The linker has been GSK3β which itself is known to increase the production of Aβ. GSK3β has been known to be primed by cdk5 so that the inhibition of cdk5 reduces Aβ toxicity. Synaptic dysfunctions are not only mediated by a decrease of acetylcholine, but also by Aβ-induced increases of presynaptic proteins. Moreover, Aβ mediates inflammatory brain processes via protein kinases.

The low benefit of drugs which target one single target structure enforced studies for a potential multitargeting. The early strategy in this field concentrated on the combination of differently acting drugs by linkers like alkyl chains. The present outcome of these studies is poor. However, combining of two drugs by a linker leads to new molecules with changed molecular properties. Resulting enlarged molecular weights influence resorption processes and brain entry properties. It will be a challenge to develop a favourable combined drug for AD therapy.

Protein kinases have been identified as mainly disease influencing target structures. Their central role in tau pathology by tau phosphorylation is extended to disease-linking processes and makes them to most interesting target structures.

Limits in the development of inhibitors of such AD-relevant protein kinases have been pointed out: the brain entry of such small molecules, toxic cellular effects which accompany also recent inhibitors and highly active molecules. The latter aspect became obvious by recent studies with GSK3β inhibitors. None of the highly active inhibitors reached clinical trials. A micromolar inhibitor seems to be more promising.

What can be the conclusion from all these points? It will be of great interest to develop a drug which itself has such multitargeting properties. As protein kinases are promising target structures further developments shall concentrate on a multitargeting protein kinase inhibitor which has to be profiled in the various ways like brain entry abilities, low cellular toxicity and finally a sufficient but not a too strong activity just to regulate the protein kinases' overactivities and not to interfere with their activities in normal cells. 1-Aza-9-oxafluorenes from a really perspective compound class on this way of a hopeful AD drug development.
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